Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.

@article{Chin2017BrachytherapyFP,
  title={Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.},
  author={Joseph L. Chin and R Bryan Rumble and Marisa Kollmeier and Elisabeth I. Heath and Jason A. Efstathiou and Tanya B. Dorff and Barry S. Berman and Andrew Feifer and Arthur D Jacques and D. Andrew Loblaw},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 15},
  pages={
          1737-1743
        }
}
  • J. Chin, R. B. Rumble, D. Loblaw
  • Published 27 March 2017
  • Medicine, Physics
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Purpose To jointly update the Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer to account for new evidence. Methods An Update Panel conducted a targeted systematic literature review and identified more recent randomized controlled trials comparing dose-escalated external beam radiation therapy (EBRT) with brachytherapy in men with prostate cancer. Results Five randomized controlled trials provided the evidence for this update. Recommendations For patients with… 

Tables from this paper

Current controversies in prostate brachytherapy for prostate cancer
TLDR
The purpose of this review is to summarize the role of LDR-BT in managing prostate cancer and to discuss patient selection in a contemporary context.
Brachytherapy for prostate cancer: Present and future.
  • J. Hannoun-levi
  • Medicine, Physics
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  • 2017
Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives
TLDR
The improved biochemical control shown in trials have resulted in EBRT plus brachytherapy to be included as a standard treatment option supported by the NCCN and ASCO guidance documents for intermediate to high risk prostate cancer.
Current status of prostate brachytherapy in Japan
  • A. Yorozu
  • Medicine, Physics
    Japanese Journal of Radiology
  • 2020
TLDR
The literature review demonstrated that brachytherapy provides superior outcomes in patients with low-risk disease in terms of biochemical prostate-specific antigen (PSA) free progression and the combination of EBRT and brachyTherapy was shown to be superior to EbrT or surgery alone for intermediate- risk disease.
Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in ontario, canada.
  • M. Corkum, G. Morton, G. Rodrigues
  • Medicine, Physics
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2020
...
...

References

SHOWING 1-10 OF 23 REFERENCES
Controversies in prostate cancer radiotherapy: consensus development.
The GU Radiation Oncologists of Canada (GUROC) had a consensus meeting in November 2000 to discuss and develop consensus on four controversial areas: risk assessment of localized prostate cancer,
Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.
TLDR
For patients with newly diagnosed low-risk or intermediate-risk prostate cancer who require or choose active treatment, LDR-BT alone is a treatment option as an alternative to EBRT alone or RP alone; and I-125 and Pd-103 are each reasonable isotope options.
Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer
TLDR
Low-risk patients had estimates of 5-year PSA outcome after treatment with RP, RT, or implant with or without neoadjuvant androgen deprivation that were not statistically different, whereas intermediate- and high- risk patients treated with RP or RT did better then those treated by implant.
Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.
TLDR
PB alone is a treatment option with equal efficacy to EBRT or RP alone in patients with newly diagnosed lowor intermediate-risk prostate cancer who require or choose active treatment.
Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.
ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.
TLDR
A planned sample size of 400 patients were randomized to one of two treatment arms and stratified by risk group, and the primary endpoint was relapse free survival (RFS) defined by biochemical criteria using the nadir+2 ng/mL threshold.
...
...